PubHawk
RMD Open February 2023 PMID 36796874

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Dinesh Khanna, Toby M Maher, Elizabeth R Volkmann, Yannick Allanore, Vanessa Smith, Shervin Assassi, Michael Kreuter, Anna-Maria Hoffmann-Vold, Masataka Kuwana, Christian Stock, Margarida Alves, Steven Sambevski, Christopher P Denton

Download social card

Mentions

7
Peak: 2 in Feb 2023
across 3 sources since Jun 2022

Extended reach

3,660
potential audience

Total likes

0

Video views

254

Mentions per month

Jun 2022 – Apr 2024

Where it's discussed

  • X / Twitter3 posts
  • Facebook3 posts
  • YouTube1 videos

AI synopsis

What people are saying

Discussions reflect a balanced recognition of the study's significance, with comments highlighting how nintedanib may slow lung decline in high-risk patients, using phrases like 'particularly helpful for those at greatest risk' and emphasizing clinical implications. The tone complements this by referencing specific risk factors and treatment benefits, illustrating thoughtful engagement and appreciation of its potential impact.

AgreementModerate agreement

Most discussions acknowledge the study's findings, especially regarding nintedanib's benefits for high-risk patients, indicating general agreement with the research conclusions.

InterestModerate interest

Participants show moderate interest by engaging with detailed analyses and emphasizing clinical relevance, rather than purely superficial comments.

EngagementModerate engagement

Posts often reference specifics of the study, such as risk factors like skin fibrosis and inflammatory markers, demonstrating a thoughtful and engaged level of discussion.

ImpactModerate impact

Engagement with the potential for improved treatment strategies and the importance of identifying high-risk patients signifies perceived meaningful impact.

Abstract in brief

  • The study evaluated how nintedanib impacted lung function decline, measured by forced vital capacity (FVC), in patients with systemic sclerosis-related interstitial lung disease (SScILD), especially those at risk of rapid deterioration.
  • Key risk factors for faster FVC decline identified included being within 18 months of first non-Raynaud symptom, having elevated inflammatory markers (like C-reactive protein), and significant skin fibrosis.
  • The results showed that patients with these risk factors experienced a quicker decline in lung function over a year, but nintedanib helped reduce this decline, particularly in those with the highest risk traits.
Read the full abstract

Top posts

Most liked on X and Bluesky
UCL Discovery
@ucl_discovery · X

Open Access UCL Research: Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression - UCL Discovery https://t.co/vO9ETXlDin

Feb 23, 2023 · 2,521 followers View post →
RC - Research
@RC_Research · X

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression https://t.co/dmPo0YU3Gs

Feb 20, 2023 · 508 followers View post →

All mentions

UCL Discovery
@ucl_discovery · X

Open Access UCL Research: Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression - UCL Discovery https://t.co/vO9ETXlDin

Feb 23, 2023 · 2,521 followers View post →
RC - Research
@RC_Research · X

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression https://t.co/dmPo0YU3Gs

Feb 20, 2023 · 508 followers View post →
Dr Sultana Abdulaziz
@drsabdulaziz · X

EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL https://t.co/LgNDos7wtL

Jun 11, 2022 · 378 followers View post →